Hospital
Broadlawns Medical Center
Broadlawns Medical Center was paid $112.67M by Medicaid between Jan 2018 and Dec 2024, across 431 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 40% of everything it billed.
33Billing provider infoBROADLAWNS MEDICAL CENTER
DES MOINES, IA 50314
DES MOINES, IA 50314
33aNPI1467447508assigned 09/14/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$112.67M
24GClaims2,153,161
24DCodes billed431
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 305,282 | $15.73M | |
| 2019 | 309,204 | $16.47M | |
| 2020 | 252,560 | $13.92M | |
| 2021 | 326,158 | $16.80M | |
| 2022 | 351,211 | $17.80M | |
| 2023 | 341,946 | $17.79M | |
| 2024incomplete | 266,800 | $14.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 40% | 454,667 | 406,053 | $44.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.2% | 73,887 | 50,573 | $8.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 52,996 | 40,454 | $7.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.6% | 169,260 | 159,216 | $6.31M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.4% | 180,901 | 170,387 | $5.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 20,982 | 18,436 | $4.61M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 2.9% | 3,661 | 1,221 | $3.21M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.0% | 27,271 | 16,605 | $2.31M |
| T1013 | Sign language or oral interpretive services, per 15 minutes | 1.7% | 44,127 | 37,873 | $1.88M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 10,646 | 9,814 | $1.41M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.1% | 20,825 | 13,522 | $1.27M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 1.0% | 12,234 | 7,321 | $1.16M |
419 more codes
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 32,509 | $1.11M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,431 | $1.07M |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 8,520 | $964K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 15,977 | $920K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13,335 | $918K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 17,283 | $757K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 9,807 | $754K |
| 20610 | <1% | 6,273 | $748K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,503 | $733K |
| 95913 | <1% | 2,613 | $685K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 34,142 | $617K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,916 | $522K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,116 | $503K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,625 | $499K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 8,113 | $497K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,264 | $480K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,057 | $446K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,311 | $401K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 4,714 | $363K |
| 95811 | <1% | 972 | $361K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,447 | $353K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,754 | $351K |
| 62323 | <1% | 1,314 | $329K | |
| 94060 | <1% | 2,760 | $314K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,822 | $314K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,541 | $312K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,308 | $311K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 697 | $300K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 13,576 | $292K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 5,050 | $285K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,652 | $261K |
| 80061 | Lipid panel | <1% | 19,663 | $261K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,475 | $257K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,154 | $243K |
| 64615 | <1% | 2,339 | $237K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 369 | $236K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,901 | $220K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,443 | $212K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,198 | $193K |
| 90686 | <1% | 14,943 | $177K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,590 | $171K |
| 95911 | <1% | 648 | $151K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,098 | $148K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,229 | $147K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,156 | $144K |
| 73630 | <1% | 11,747 | $141K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 165,097 | $135K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,796 | $133K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 609 | $130K |
| 20553 | <1% | 926 | $129K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,496 | $126K |
| J0897 | Injection, denosumab, 1 mg | <1% | 250 | $108K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 319 | $105K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 265 | $104K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,598 | $101K |
| 99460 | <1% | 1,749 | $99K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,122 | $99K |
| 80050 | General health panel | <1% | 1,854 | $94K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,565 | $94K |
| 95886 | <1% | 4,369 | $91K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,759 | $88K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,231 | $86K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,911 | $86K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,264 | $85K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 515 | $81K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,444 | $80K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 130 | $79K |
| 94726 | <1% | 2,703 | $74K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,056 | $70K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 447 | $68K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 330 | $68K |
| 73610 | <1% | 5,283 | $63K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 272 | $63K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,183 | $60K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,697 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 51,176 | $60K |
| 0002A | <1% | 1,608 | $59K | |
| 20552 | <1% | 635 | $59K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 891 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,102 | $55K |
| 92134 | <1% | 6,005 | $55K | |
| 66821 | <1% | 282 | $54K | |
| 0001A | <1% | 1,687 | $53K | |
| 98929 | <1% | 2,257 | $50K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,599 | $50K |
| V2020 | Frames, purchases | <1% | 2,216 | $49K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,904 | $46K |
| 74019 | <1% | 3,581 | $45K | |
| 91320 | <1% | 762 | $44K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 500 | $43K |
| 92083 | <1% | 1,899 | $42K | |
| 73562 | <1% | 3,566 | $42K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,262 | $40K |
| 86481 | <1% | 797 | $39K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,796 | $38K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 782 | $38K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 82 | $38K |
| 92557 | <1% | 377 | $37K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,348 | $36K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 808 | $36K |
| 90716 | <1% | 630 | $35K | |
| 99223 | Prolong inpt eval add15 m | <1% | 312 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 23,007 | $34K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,849 | $34K |
| 86780 | <1% | 1,878 | $34K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 339 | $34K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,973 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 33,895 | $32K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 293 | $32K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 340 | $31K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,004 | $31K |
| 77065 | Tomosynthesis, mammo | <1% | 845 | $30K |
| 92133 | <1% | 4,078 | $27K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 51 | $27K |
| 97597 | <1% | 372 | $27K | |
| 92136 | <1% | 2,192 | $26K | |
| 73130 | <1% | 2,385 | $25K | |
| 0124A | <1% | 1,077 | $25K | |
| 90480 | <1% | 1,036 | $24K | |
| 99220 | <1% | 235 | $24K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 503 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 700 | $24K |
| 73030 | <1% | 2,543 | $24K | |
| 76801 | <1% | 350 | $23K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 514 | $23K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 16 | $23K |
| 72100 | <1% | 2,016 | $23K | |
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | <1% | 1,160 | $22K |
| 87631 | <1% | 2,035 | $22K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 326 | $22K |
| 65855 | <1% | 117 | $22K | |
| 76642 | <1% | 621 | $19K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 238 | $19K |
| 69210 | <1% | 1,154 | $19K | |
| 11721 | <1% | 658 | $19K | |
| 95800 | <1% | 315 | $18K | |
| 86900 | <1% | 3,121 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,534 | $18K |
| 97161 | <1% | 306 | $17K | |
| 99217 | <1% | 331 | $16K | |
| 0003A | <1% | 573 | $15K | |
| 64493 | <1% | 30 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,996 | $14K |
| 73110 | <1% | 1,226 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 1,518 | $14K |
| 90651 | <1% | 391 | $14K | |
| 83655 | <1% | 1,588 | $13K | |
| 87070 | <1% | 1,722 | $13K | |
| 99219 | <1% | 180 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 229 | $13K |
| 95819 | <1% | 101 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 427 | $13K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 293 | $13K |
| 90677 | <1% | 159 | $12K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 374 | $12K |
| 81001 | <1% | 7,396 | $11K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 116 | $11K |
| 94729 | <1% | 3,659 | $11K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 591 | $11K |
| 90750 | <1% | 129 | $11K | |
| 84439 | <1% | 3,370 | $10K | |
| 95813 | <1% | 83 | $10K | |
| 93971 | <1% | 374 | $10K | |
| 74018 | <1% | 1,085 | $10K | |
| 29405 | <1% | 51 | $10K | |
| 99188 | <1% | 788 | $9K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 282 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 878 | $9K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 84 | $8K |
| D0460 | <1% | 399 | $8K | |
| 86592 | <1% | 181 | $8K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 89 | $8K |
| 64483 | <1% | 26 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $7K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,409 | $7K |
| 96136 | <1% | 458 | $7K | |
| 90656 | <1% | 1,519 | $7K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 138 | $7K |
| 98960 | <1% | 217 | $7K | |
| D1206 | Topical application of fluoride varnish | <1% | 250 | $7K |
| 0072A | <1% | 218 | $7K | |
| 95115 | <1% | 202 | $6K | |
| 99225 | <1% | 224 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 109 | $6K |
| 85060 | <1% | 372 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 104 | $6K |
| 93970 | <1% | 72 | $6K | |
| 86480 | <1% | 86 | $5K | |
| 96417 | <1% | 124 | $5K | |
| 52000 | <1% | 22 | $5K | |
| 92567 | <1% | 1,159 | $5K | |
| 99462 | <1% | 153 | $5K | |
| 88304 | <1% | 394 | $5K | |
| 96367 | <1% | 124 | $5K | |
| 81025 | <1% | 9,581 | $5K | |
| 88342 | <1% | 212 | $4K | |
| 0071A | <1% | 157 | $4K | |
| 90746 | <1% | 86 | $4K | |
| 99443 | <1% | 594 | $4K | |
| 93017 | <1% | 97 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,658 | $4K |
| 99442 | <1% | 550 | $4K | |
| 90632 | <1% | 127 | $4K | |
| 90678 | <1% | 13 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,937 | $4K |
| 70486 | <1% | 67 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 105 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,125 | $3K |
| 92587 | <1% | 12 | $3K | |
| 71250 | <1% | 75 | $3K | |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 139 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 74 | $3K |
| 73140 | <1% | 345 | $3K | |
| 0111A | <1% | 108 | $3K | |
| 54150 | <1% | 36 | $3K | |
| 90670 | <1% | 3,028 | $3K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,025 | $3K |
| 80074 | <1% | 425 | $3K | |
| 72141 | <1% | 46 | $3K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 18 | $3K |
| 76775 | <1% | 118 | $2K | |
| 95974 | <1% | 34 | $2K | |
| 00142 | <1% | 50 | $2K | |
| 59025 | Fetal non-stress test | <1% | 26 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 31 | $2K |
| 99483 | Prolong outpt/office vis | <1% | 50 | $2K |
| D0120 | Dental checkup, returning patient | <1% | 68 | $2K |
| 71271 | <1% | 43 | $2K | |
| 88307 | <1% | 30 | $2K | |
| 92002 | <1% | 37 | $2K | |
| 77002 | <1% | 207 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,055 | $2K |
| 96127 | <1% | 607 | $2K | |
| 95976 | <1% | 47 | $2K | |
| 73080 | <1% | 148 | $2K | |
| 85610 | <1% | 4,575 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,242 | $2K |
| 94010 | <1% | 205 | $2K | |
| 93225 | <1% | 16 | $2K | |
| 87210 | <1% | 284 | $1K | |
| 90710 | <1% | 397 | $1K | |
| 0112A | <1% | 37 | $1K | |
| 96130 | <1% | 110 | $1K | |
| V2756 | Eye glass case | <1% | 1,325 | $1K |
| 92235 | <1% | 23 | $1K | |
| 82043 | <1% | 2,721 | $1K | |
| 76536 | <1% | 35 | $1K | |
| 90836 | <1% | 29 | $1K | |
| 82950 | <1% | 140 | $1K | |
| 92020 | <1% | 261 | $1K | |
| 0004A | <1% | 55 | $1K | |
| D1110 | Prophylaxis - adult | <1% | 15 | $1K |
| 72040 | <1% | 97 | $1K | |
| 90734 | <1% | 119 | $971.50 | |
| 90715 | <1% | 1,066 | $932.59 | |
| D1120 | Dental cleaning, child | <1% | 19 | $921.31 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 4,779 | $899.32 |
| 82728 | <1% | 1,295 | $890.94 | |
| 88142 | <1% | 303 | $851.44 | |
| S0201 | Partial hospitalization services, less than 24 hours, per diem | <1% | 133 | $826.28 |
| 87428 | <1% | 31 | $811.51 | |
| 73564 | <1% | 97 | $800.36 | |
| 84460 | <1% | 2,842 | $780.21 | |
| 90662 | <1% | 150 | $755.61 | |
| 93227 | <1% | 29 | $753.82 | |
| 73501 | <1% | 27 | $749.53 | |
| 82570 | <1% | 2,648 | $749.32 | |
| 64494 | <1% | 30 | $738.77 | |
| 84450 | <1% | 2,527 | $689.42 | |
| G0008 | Administration of influenza virus vaccine | <1% | 739 | $681.92 |
| 71101 | <1% | 54 | $678.49 | |
| 85046 | <1% | 689 | $650.34 | |
| 76514 | <1% | 272 | $644.69 | |
| 93018 | <1% | 42 | $633.24 | |
| 73502 | <1% | 60 | $624.30 | |
| 90707 | <1% | 55 | $606.00 | |
| 83550 | <1% | 1,294 | $590.35 | |
| 84702 | <1% | 346 | $577.17 | |
| 81003 | <1% | 10,100 | $566.45 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 138 | $554.20 |
| 96103 | <1% | 317 | $548.11 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 38 | $540.91 |
| 99201 | <1% | 27 | $522.66 | |
| 85004 | <1% | 146 | $495.27 | |
| 83540 | <1% | 1,303 | $468.51 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 92 | $433.68 |
| 90671 | <1% | 853 | $432.95 | |
| 0012A | <1% | 55 | $431.55 | |
| 99418 | Prolong nursin fac eval 15m | <1% | 12 | $425.62 |
| 96131 | <1% | 26 | $417.68 | |
| 51798 | <1% | 206 | $412.62 | |
| 85027 | <1% | 1,317 | $405.10 | |
| 82105 | <1% | 239 | $402.59 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 425 | $396.22 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $382.30 |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 16 | $375.25 |
| 96380 | <1% | 36 | $354.24 | |
| 82677 | <1% | 155 | $340.32 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 20 | $338.65 |
| 87340 | <1% | 445 | $336.10 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 43 | $333.23 |
| 87328 | <1% | 42 | $306.15 | |
| 90620 | <1% | 14 | $304.48 | |
| 87077 | <1% | 91 | $295.53 | |
| 98928 | <1% | 21 | $294.39 | |
| D0274 | Bitewings - four radiographic images | <1% | 12 | $290.94 |
| 85018 | <1% | 1,859 | $289.26 | |
| 87653 | <1% | 74 | $283.04 | |
| 86706 | <1% | 420 | $274.08 | |
| 87329 | <1% | 42 | $265.42 | |
| 83880 | <1% | 165 | $262.60 | |
| 84484 | <1% | 8,126 | $232.99 | |
| 90723 | <1% | 1,838 | $230.64 | |
| 93000 | <1% | 16 | $229.25 | |
| 82652 | <1% | 16 | $225.75 | |
| 83735 | <1% | 792 | $220.40 | |
| 86336 | <1% | 155 | $219.36 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 192 | $217.02 |
| 85048 | <1% | 149 | $200.04 | |
| 99173 | <1% | 54 | $192.07 | |
| 82077 | <1% | 4,241 | $183.15 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 24 | $183.01 |
| D0330 | Panoramic radiographic image | <1% | 28 | $181.76 |
| 77085 | <1% | 16 | $175.34 | |
| 87150 | <1% | 52 | $171.02 | |
| 76937 | <1% | 17 | $164.49 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 327 | $160.66 |
| 99307 | <1% | 30 | $156.48 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 620 | $146.40 |
| 90619 | <1% | 33 | $146.04 | |
| 73560 | <1% | 24 | $145.12 | |
| 99441 | <1% | 12 | $127.33 | |
| 86803 | <1% | 314 | $123.37 | |
| 73565 | <1% | 17 | $119.86 | |
| 86850 | <1% | 2,317 | $114.12 | |
| 73590 | <1% | 14 | $111.93 | |
| 92250 | <1% | 25 | $110.39 | |
| 72072 | <1% | 13 | $107.23 | |
| 83690 | <1% | 4,372 | $104.30 | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 189 | $101.63 |
| 83020 | <1% | 12 | $99.52 | |
| 96401 | <1% | 71 | $94.79 | |
| 95012 | <1% | 191 | $89.17 | |
| 84163 | <1% | 68 | $88.30 | |
| 0011A | <1% | 31 | $86.06 | |
| 85014 | <1% | 1,581 | $85.82 | |
| 82607 | <1% | 42 | $85.34 | |
| 80069 | <1% | 26 | $75.27 | |
| 80179 | <1% | 1,218 | $71.89 | |
| 80143 | <1% | 1,206 | $71.89 | |
| 86308 | <1% | 365 | $67.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,594 | $64.83 |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 40 | $53.74 |
| 36410 | <1% | 17 | $43.72 | |
| 86140 | <1% | 2,311 | $42.16 | |
| 86901 | <1% | 3,121 | $41.41 | |
| 83970 | <1% | 124 | $40.00 | |
| 85730 | <1% | 998 | $34.45 | |
| 87081 | <1% | 101 | $32.95 | |
| 82075 | <1% | 45 | $29.07 | |
| 86704 | <1% | 159 | $28.84 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 538 | $22.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 39 | $18.00 |
| 82746 | <1% | 13 | $14.25 | |
| 86762 | <1% | 561 | $13.94 | |
| 82150 | <1% | 105 | $11.60 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 113 | $11.40 |
| 84100 | <1% | 95 | $11.12 | |
| 82550 | <1% | 295 | $6.30 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 323 | $5.10 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 661 | $5.09 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 75 | $4.00 |
| 85652 | <1% | 25 | $2.57 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 40 | $1.59 |
| 90713 | <1% | 961 | $0.40 | |
| 0502F | 0% | 3,597 | $0.00 | |
| 90461 | 0% | 6,971 | $0.00 | |
| 91300 | 0% | 4,490 | $0.00 | |
| 90648 | 0% | 2,767 | $0.00 | |
| 90633 | 0% | 1,521 | $0.00 | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | 0% | 193 | $0.00 |
| 90685 | 0% | 84 | $0.00 | |
| 80076 | 0% | 136 | $0.00 | |
| 90700 | 0% | 176 | $0.00 | |
| 91311 | 0% | 193 | $0.00 | |
| 91312 | 0% | 278 | $0.00 | |
| 86709 | 0% | 108 | $0.00 | |
| 91321 | 0% | 36 | $0.00 | |
| 90380 | 0% | 26 | $0.00 | |
| 93226 | 0% | 16 | $0.00 | |
| 84145 | 0% | 31 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 34 | $0.00 |
| 82565 | 0% | 15 | $0.00 | |
| 87186 | 0% | 31 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 2,294 | $0.00 |
| 83605 | 0% | 210 | $0.00 | |
| 90680 | 0% | 2,637 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 290 | $0.00 |
| 94761 | 0% | 416 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 87 | $0.00 |
| 0500F | 0% | 76 | $0.00 | |
| 90744 | 0% | 59 | $0.00 | |
| 91307 | 0% | 77 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 83 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| 90698 | 0% | 149 | $0.00 | |
| 86141 | 0% | 13 | $0.00 | |
| 90688 | 0% | 162 | $0.00 | |
| 0503F | 0% | 54 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 145 | $0.00 |
| 85660 | 0% | 13 | $0.00 | |
| 82962 | 0% | 79 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 49 | $0.00 |
| 96376 | 0% | 37 | $0.00 | |
| 99024 | 0% | 15 | $0.00 | |
| 85379 | 0% | 13 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| 90381 | 0% | 25 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANDRACCHIA, VINCENT (CHIEF MEDICAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Broadlawns Medical Center | Des Moines, IA | $13.21M |
| Broadlawns Medical Center | Des Moines, IA | $4.18M |
| Broadlawns Medical Center | Des Moines, IA | $2.43M |
| Broadlawns Medical Center | Des Moines, IA | $1.75M |
| Broadlawns Medical Center | Des Moines, IA | $1.55M |
| Broadlawns Medical Center | Des Moines, IA | $169K |
| Broadlawns Medical Center | Des Moines, IA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.